Bioxcel Therapeutics, Inc. · NASDAQ:BTAI
Bioxcel Therapeutics — Investor Presentation (August 2025)
15 slides from Bioxcel Therapeutics's investor presentation, Aug 11, 2025
Slide 1: BXCL501 Commercial Opportunity in the At-Home Setting for Bipolar Disorders and Schizophrenia
® BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com August 2025 BXCL501 Commercial Opportunity in the At-Home Setting for Bipolar Disorders and Schizophrenia NASDAQ: BTAI
Slide 2: The At-Home Market for BXCL501 in Schizophrenia and Bipolar Disorders: Summary
The potential for BXCL501 in the at-home setting reflects significant unmet need and attractiveness to patients Anticipated Episodic Patient Choice (Future Market) (% of Episodes, Market research, n=240) 80% 20% BXCL501 Other • Our market research indicates approximately 3 episodes of agitation per
Slide 3: A behavioral emergency with highly variable clinical definitions and diagnoses
A behavioral emergency with highly variable clinical definitions and diagnoses1-3 Agitation Characteristics Emotional signs and symptoms • Hyperresponsiveness • Racing thoughts • Emotional tension Agitation is characterized by1 Behavioral signs and symptoms • Inability to stay calm or still • Motor
Slide 4: Agitation episodes expected to occur 3-4 times per month based on multiple data sources
35% 53% 12% Mild Moderate Severe Schizophrenia (n=20) 35 Episodes per year (~3/month) Bipolar Disorder (n=60) 38 Episodes per year (~3/month) 1Source: InVibe Feb 2023 Q4: In the past month, about how many agitation episodes [IF PATIENT SHOW “have you” IF CG SHOW “has your loved one”] experienced? Q5
Slide 5: At-Home Intervention: Early Intervention May Prevent Severity Escalation
Potentially reduced ER visits, hospitalizations, or first responder interventions At-Home Intervention: Early Intervention May Prevent Severity Escalation 5 PRE-AGITATION AGITATION INITIATION MILD MODERATE SEVERE OPTIMAL INTERVENTION BXCL501 CLINICAL DEVELOPMENT AT HOME SETTING 23M EPISODES1 1Number
Slide 6: Market seeks effective, fast-acting, more tolerable treatment for agitation at home
The available drugs either work too slowly or have unacceptable side effects.” – Psychiatrist 0% 10% 20% 30% 40% 50% 60% Key unmet needs in SCZ 16% 12% View lack of current effective and fast acting treatments to be the primary unmet need Are concerned with the side effects of current treatments Men
Slide 7: BXCL501 Peak Market Share Based on Target at-home Product Profile
BXCL501 Peak Market Share Based on Target at-home Product Profile Agitation associated with ~16% Bipolar Disorder & Schizophrenia Methodology: Current Management: Respondents provide information about their patients and the treatment of each indication, including: Perceived unmet need, Estimated pat
Slide 8: Recognition and Treatment of Agitation
Patients experiencing agitation indicate that they are not typically diagnosed, nor treated, for this symptom. This creates an opportunity and need for HCP education and market conditioning. Recognition and Treatment of Agitation 8 Q1. Have you ever been diagnosed with agitation specifically? This c
Slide 9: Patients Perspectives of At-Home Agitation
[I]t feels like there's something inside of me telling me there's something wrong, and I can't sit still, and I feel like my body's about to jump out of my skin. It's just really annoying, and you get short-tempered because of it and angry and snappy at people. It's hard to describe because you can'
Slide 10: Advance Knowledge of Agitation Episodes
22% 78% Yes No 11% 89% Mild 39% 61% 28% 72% Advance Knowledge of Agitation Episodes (% of Episodes, n=240*) * These data are compiled from 3 episodes described by each patient (N=80 pts/cgs *3 = 240) Caregivers and patients were equally likely to have advance knowledge of an episode (22% for both gr
Slide 11: Episode Intervention Target
Patients indicate that they want to manage the episode with BXCL501 either just before or at the first sign of escalation in the at-home setting. Episode Intervention Target I would love to be able to have it available when I knew an episode was coming. That it would help bite it in the butt, so to
Slide 12: Patients Preference Estimate
Medications Used to Treat Agitation Episodes (Current Market) (% of Episodes, n=240) Anticipated Uptake for BXCL501 (Future Market) (% of Episodes, n=240) 80% 33% 17% 14% 13% 6% 4% 0% 20% 40% 60% 80% 100% BXCL501 Anti-anxiety Anti-depressants Mood stabilizers Anti-psychotic Other None 31% 24% 20% 15
Slide 13: Retail Agitation Markets & Pricing Considerations
$1,419.00 $1,110.88 $315.00 $0.00 $200.00 $400.00 $600.00 $800.00 $1,000.00 $1,200.00 $1,400.00 $1,600.00 Rexulti Auvelity BXCL501 for BP/SCHZ Agitation At-Home Pricing Landscape* Price per 30 days of Therapy Current and development agitation products (chronic) cost over $1400/month. These products
Slide 14: Provisional Targeting Model
Provisional Targeting Model 14 Among the highest deciles of Bipolar & Schizophrenia patient Dx volume, 70% are managed by psychiatrists, with 8.1k total HCP targets. 50-70 discrete field FTEs can cover these targets Sources: Clarivate Claims, FY2021; Definitive December 2022 BP/SCZ Patient Dx Volume
Slide 15: Forward-Looking Statements
Forward-Looking Statements 15 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) intends such forward-looking statements to be covered by the safe harbor provision
BioXcel Therapeutics — Investor Presentation (August 2025) on 6ix